Artiva Biotherapeutics’ Post

The below is a relatively old blog on developing and evaluating CAR-T . Wishing all the budding scientists in cell and gene therapy a insightful weekend read. #CART #CD19 #Genetherapy #FACS #cancertherapy #assaydevelopment #celltherapy https://lnkd.in/g6dzwBP8

Immusoft has dosed the first patient with an engineered B cell therapy—ISP-001 for MPS I (Mucopolysaccharidosis type I). This approach has several potential advantages over current gene and cell therapies.

Here’s a quick Q&A with Cell & Gene if you are interested in learning more about Artiva’s Manufacturing First approach:

What's trending this week in the #cellandgenetherapy sector? 🩸 Gene therapy to treat hemophilia B is recommended for conditional marketing authorization by EMA CHMP ✅ The FDA approved CAR-T cell therapy to treat mantle cell lymphoma 🤝 New clinical collaboration agreement for cell therapy to treat head and neck cancer Read the full stories below and subscribe to our Sector Vector newsletter for more weekly cell and gene therapy clinical, business, and manufacturing news: https://lnkd.in/eD7ZNaU The EMA CHMP has recommended granting a conditional marketing authorisation for Pfizer's Durveqtix (fidanacogene elaparvovec), a gene therapy to treat severe and moderately severe hemophilia B. https://lnkd.in/eU6FfmCj The FDA granted an expanded indication approval to Bristol Myers Squibb for its CAR-T cell therapy to treat adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy. https://lnkd.in/eMq-Vp8j Galapagos and Adaptimmune have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform. https://lnkd.in/gFp5qdY5

T cells are essential in the adaptive immune response, and there is particular interest in genetically engineering these cells for therapy against cancer and other diseases. STEMCELL Technologies provides tools for a complete #Tcell workflow—from cell sourcing and isolation, to gene editing, expansion, and analysis—helping you move your research forward with confidence. #Immunology #CellTherapy https://lnkd.in/gBUbWSYP

NEW ARTICLE: The Unique Power of Genetically Unmodified NK Cell Therapy Their relatively short life cycle, and lackluster capacity to expand upon activation compared to T cells has many experts in the industry wondering if there is a viable path forward for Natural Killer (NK) cell therapies. While they may not be the be as long-lasting, or immunogenically robust as their T cell counterparts, a core feature of NK cell biology offers a significant advantage over T cells: they do not recognize targets through a TCR… In this article, we discuss exactly why this is so crucial for cell therapy, what the exact advantages are, and the key biotech players that are taking advantage of it. https://lnkd.in/e4HPPy8b

Cell and Gene Therapies are emerging as new modes of treatment options for various indications. Cell and Gene therapies encompass CAR-T, CAR-NK, CAR-M as well as RNA therapies. Cell & Gene Therapies are set to rule the market within the next few years. In 2021, the global market for CAR-T cell therapy was estimated to be 1.5 billion USD and it is forecasted to grow to approximately 7.6 billion USD by 2026, demonstrating a compound annual growth rate (CAGR) of 39.1%. (https://lnkd.in/gXuSkwhy) As the world proceeds with an increased requirement for these new therapies, Lextro Bio Solutions is all set to take up this new challenge and help accelerate your drug discovery in this domain. At Lextro we offer the development of scFv, and RNAi therapies as well as the evaluation of targeted delivery of gene therapy constructs to desired cell populations. To know more please write to Lextro Bio at (contact@lextrobio.com) #cellandgenetherapy #CART #CGT #scFv #RNAi #CARNK #CARM #Lextrobio

What if we can reverse or slow down Alzheimer's disease? Day 20 of celebrating good news in cell and gene therapies: NKGen Biotech, Inc.'s autologous enhanced natural killer cell therapy cleared to start Phase 2 clinical trial for moderate Alzheimer's disease! The process of manufacturing these therapies involves expanding and activating patients’ own NK cells to cross the blood–brain barrier through a simple peripheral IV and remove amyloid, p-tau, and alpha-synuclein proteins. This approach has successfully reduced neuroinflammation without any treatment related side effects during Phase 1. Despite only receiving 4 doses, 90% of patients demonstrated improvement or maintained stable cognitive function. Congratulations on being cleared to start Phase 2 of the trial and hopefully the candidate will continue to demonstrate great safety and efficacy! May 20th is homophonic to "I love you" in Chinese. Here is hoping that no one will have to suffer from loved ones forgetting them due to Alzheimer's anymore ❤️ https://lnkd.in/d6t6ZGdG If anyone is heading to ISCT, International Society for Cell & Gene Therapy in Vancouver, would love to bounce ideas and learn more about the important work different researchers and companies are doing to drive patient impact! #CGT #NKcells #celltherapies #Alzheimers #celebrate #monthofCGTcelebrations

What's new in the #cellandgenetherapy sector? This week, we've seen more notable developments in cell therapy programs. ✅CAR-T cell therapy receives EMA CHMP recommendation to be a second-line treatment for multiple myeloma 🧫First-ever IND clearance of an allogeneic off-the-shelf NK cell therapy for an autoimmune disease Read the full stories below and subscribe to our Sector Vector newsletter for more weekly cell and gene therapy clinical, business, and manufacturing news: https://lnkd.in/eD7ZNaU This week, the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the expansion of Legend Biotech's and Johnson & Johnson's CAR-T cell therapy to treat adult patients with r/r multiple myeloma who received at least one prior treatment. https://lnkd.in/eH47deaQ The FDA has granted fast-track designation to Artiva Biotherapeutics' AlloNK program to treat lupus nephritis. The decision marks the first IND clearance of an allogeneic, off-the-shelf NK cell therapy in autoimmune disease. https://lnkd.in/gXGDPAmE #Celltherapy

Genprex begins patient dosing in phase 2a expansion of Acclaim-1 study of Reqorsa Therapy in combo with Tagrisso to treat NSCLC